JP2017519727A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519727A5
JP2017519727A5 JP2016566962A JP2016566962A JP2017519727A5 JP 2017519727 A5 JP2017519727 A5 JP 2017519727A5 JP 2016566962 A JP2016566962 A JP 2016566962A JP 2016566962 A JP2016566962 A JP 2016566962A JP 2017519727 A5 JP2017519727 A5 JP 2017519727A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
thieno
triazolo
chlorophenyl
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016566962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519727A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/060200 external-priority patent/WO2015169951A1/en
Publication of JP2017519727A publication Critical patent/JP2017519727A/ja
Publication of JP2017519727A5 publication Critical patent/JP2017519727A5/ja
Pending legal-status Critical Current

Links

JP2016566962A 2014-05-08 2015-05-08 チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 Pending JP2017519727A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461990457P 2014-05-08 2014-05-08
US61/990,457 2014-05-08
US201462012048P 2014-06-13 2014-06-13
US62/012,048 2014-06-13
US201462080751P 2014-11-17 2014-11-17
US62/080,751 2014-11-17
US201462086400P 2014-12-02 2014-12-02
US62/086,400 2014-12-02
US201562150044P 2015-04-20 2015-04-20
US62/150,044 2015-04-20
PCT/EP2015/060200 WO2015169951A1 (en) 2014-05-08 2015-05-08 Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds

Publications (2)

Publication Number Publication Date
JP2017519727A JP2017519727A (ja) 2017-07-20
JP2017519727A5 true JP2017519727A5 (enExample) 2018-06-14

Family

ID=53191652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566962A Pending JP2017519727A (ja) 2014-05-08 2015-05-08 チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法

Country Status (11)

Country Link
US (1) US9968619B2 (enExample)
EP (1) EP3139959A1 (enExample)
JP (1) JP2017519727A (enExample)
KR (1) KR20170002610A (enExample)
CN (1) CN106852120A (enExample)
AU (1) AU2015257658A1 (enExample)
BR (1) BR112016026046A8 (enExample)
CA (1) CA2947970A1 (enExample)
MX (1) MX2016014574A (enExample)
RU (1) RU2016147946A (enExample)
WO (1) WO2015169951A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102216288B1 (ko) 2013-03-15 2021-02-18 인사이트 홀딩스 코포레이션 Bet 단백질 저해제로서의 삼환식 복소환
ES2635560T3 (es) 2013-07-08 2017-10-04 Incyte Holdings Corporation Heterociclos tricíclicos como inhibidores de la proteína NET
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
PT3134403T (pt) 2014-04-23 2020-05-18 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas como inibidores das proteínas bet
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
EP4118431A1 (de) * 2020-03-12 2023-01-18 Heinrich-Heine-Universität Düsseldorf Inhibition von fkbp1a zur therapie des triple-negativen mammakarzinoms
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
BR112023025562A2 (pt) 2021-06-08 2024-02-20 Poseidon Innovation Llc Compostos anticâncer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039802D1 (de) * 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
CA2412776C (en) 2000-06-16 2011-03-15 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
JP5478262B2 (ja) * 2007-12-28 2014-04-23 田辺三菱製薬株式会社 抗癌剤
CN104311562B (zh) 2010-05-14 2017-07-04 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US20130345145A1 (en) * 2011-03-10 2013-12-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Atip3 and biologically active fragments thereof for use in the treatment of cancer
CA2877434A1 (en) 2012-06-25 2014-01-03 Oncoethix Sa Method of treating lymphoma using thienotriazolodiazepine compounds
CA2876241A1 (en) * 2012-06-27 2014-01-03 The Curators Of The University Of Missouri Induction of estrogen receptor beta by cholesterol biosynthesis inhibitors and methods of treatment of cancer
BR112015006537A2 (pt) 2012-09-28 2017-07-04 Oncoethix Sa dispersão sólida, formulação farmacêutica, cápsula farmacêutica, e, tablete farmacêutico
ES2656640T3 (es) * 2012-10-04 2018-02-27 Ab Science Uso de masitinib en combinación con gemcitabina para tratamiento de un subgrupo de pacientes que sufren de cáncer pancreático
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
WO2015018523A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa A novel bet-brd inhibitor for treatment of solid tumors

Similar Documents

Publication Publication Date Title
JP2017519727A5 (enExample)
RU2016147946A (ru) Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений
JP2017529332A5 (enExample)
RU2017100921A (ru) Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина
CY1125110T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
JP2013510123A5 (enExample)
JP2012136540A5 (enExample)
RU2014124184A (ru) Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5
JP2013510124A5 (enExample)
JP2016530283A5 (enExample)
JP2016529246A5 (enExample)
JP2013529611A5 (enExample)
JP2014518544A5 (enExample)
JP2018501315A5 (enExample)
RU2014105577A (ru) Капсулированная лекарственная форма, содержащая монтелукаст и левоцетиризин
JP2016516067A5 (enExample)
PH12020500327A1 (en) Macrocyclic mcl-1 inhibitors and methods of use
JP2017517579A5 (enExample)
JP2019512535A5 (enExample)
JP2015504091A5 (enExample)
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
CY1123346T1 (el) Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα
CO6612185A2 (es) Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos
CN110267954A (zh) 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途